KaloBios Pharmaceuticals (KBIO) Here It Goes Again; SeaChange Intl (SEAC) Above-Consensus Earnings


KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) stock soared more than 25% in after-hours trading Thursday as the company said that it will receive from investors about $8.2 million in gross proceeds in exchange of 280,170 of its shares

KaloBios also said that it will acquire benznidazole, a Chagas Disease drug, from Savant Neglected Diseases, LLC for an upfront payment of $2 million plus milestones and sales royalties.

KBIO stock finished the regular session at $29.32, down $1.65 (or -5.33%), with a total volume of 921,470 shares traded during the day, a decrease in activity versus its average volume (3m) of 1,840,540

KaloBios Pharmaceuticals, a biopharmaceutical company, has 4.12M Shares Outstanding, Market Capitalization (intraday) of $120.91M and KBIO stock 52-week range is between $0.44 and $45.82 per share



SeaChange International, Inc. (Nasdaq:SEAC) delivered better-than-expected quarterly financial results and returned to operating profitability in the period

For its third quarter fiscal 2016 (preliminary results), SeaChange posted revenue of $28.7 million and non-GAAP (excluding non-recurring items) net income of $0.4 million, or $0.01 per diluted share, topping the Capital IQ Consensus estimate of ($0.04) loss per share for the period

SEAC stock closed at $6.56, down $0.14 (or -2.09%), and 116,647 of its shares exchanged hands on Thursday’s trading session

SeaChange International, which provides multi-screen video products and services, has 33.60M Shares Outstanding, Market Capitalization (intraday) of $220.39M and SEAC stock one-year range is from $5.30 to 8.55 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/